Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder.

Contributions: JMM, MBF, BAP, TMO, MB, and CG made substantial contributions to the conception of the work and interpretation of the data and reviewed it for critically important intellectual content. JS, MAD, QZ, and PL made substantial contributions to the conception of the work, acquisition of the data, analysis, and interpretation of the data, and reviewed it for critically important intellectual content. JA drafted the work, revised it for critically important intellectual content, and made contributions to interpretation of the data. All authors approved the final version to be published, and agree to be accountable for all aspects of the work. Potential conflicts of interest: The International Committee of Medical Journal Editors’ (ICMJE) Potential Conflicts of Interests forms for the authors are available for download at: http://www.drugsincontext.com/wp-content/uploads/2015/05/dic.212279-COI.pdf. All authors are employees and stockholders in Eli Lilly and Company. Funding declaration: This study was sponsored by Eli Lilly and Company, Indianapolis, IN, USA. Trial registration numbers: NCT00840034, NCT01185340, NCT01187407, NCT01173601 Peer review comments to author: 23 February 2015; Drugs in Context is published by Just Medical Media Ltd. Registered office: Undermount, Rydal, Ambleside, Cumbria, LA22 9LT, UK Just Medical Media Limited is registered in England Number 6891187. VAT GB 945 1713 22 For all manuscript and submissions enquiries, contact Julia Savory, Head of Digital Publishing and Submissions Management moc.aidemlacidemtsuj@ailuj For all permissions, rights, and reprints, contact Stephen I’Anson, Commercial Director moc.aidemlacidemtsuj@evets